Immunogenicity and Safety of Sabin-IPV Replacement Vaccination
Overview
This study replaced the 2nd and 3rd dose of Salk-IPV (produced by Sanofi) with Sabin-IPV (produced by CNBG) and then reviewed the safety and immunogenicity of the vaccination, aiming to acquire scientific evidence for the feasibility of immunization involving different viral strains replacement.
Full Title of Study: “a Randomized, Controlled Clinical Trial of Immunogenicity and Safety of Sabin-based Inactivated Polio Vaccine Replacing Salk-based Inactivated Polio Vaccine”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: Single (Outcomes Assessor)
- Study Primary Completion Date: December 28, 2018
Detailed Description
It is required by China Food and Drug Administration (CFDA) that considering in the real situation IPV receivers may be immuned by different viral strains of this vaccine, a phase 4 clinical trial aiming to demonstrate the safety and immunogenicity of the immunization schedule should be carried out. To be specific, the subjects were divided into 2 groups. Group 1 received Salk-IPV+Sabin-IPV+Sabin-IPV respectively at the age of 2,3,4 months old. Group 2 received Salk-IPV+Salk-IPV+Salk-IPV respectively at the age of 2,3,4 months old. Blood sample was collected before vaccination and 30 days after the third dose of vaccination. Neutralization antibody against type I, Type II and Type III poliomyelitis virus were detected to evaluate the seroprotection rates and antibody geometric mean concentrations. The safety of both immunization schedule will also been monitored.
Interventions
- Biological: Inactivated Polio Vaccine
- Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
Arms, Groups and Cohorts
- Experimental: group 1
- 180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Sabin-IPV; 3rd: Sabin-IPV
- Active Comparator: group 2
- 180 2-month-old subjects will be enrolled with vaccination schedule as follows: 1st: Salk-IPV; 2nd: Salk-IPV; 3rd: Salk-IPV
Clinical Trial Outcome Measures
Primary Measures
- Seroconversion rate
- Time Frame: 4 months
- determine the seroconversion rate of both groups
Secondary Measures
- Neutralizing antibody titers
- Time Frame: 4 months
- Measure neutralizing antibody titers against poliovirus type I, II and III
Participating in This Clinical Trial
Inclusion Criteria
- subjects aged from 60 days to 89 days old at the date of recruitment; – with informed consent signed by parent(s) or guardians; – parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions; – subjects did not receive any vaccines within 14 days; – axillary temperature ≤37.0℃ Exclusion Criteria:
- allergic to any ingredient of vaccine or with allergy history to any vaccine; – acute febrile disease or infectious disease; – serious chronic diseases; – any other factor that makes the investigator determines the subject is unsuitable for this study;
Gender Eligibility: All
Minimum Age: 60 Days
Maximum Age: 89 Days
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- China National Biotec Group Company Limited
- Collaborator
- Beijing Institute of Biological Products Co Ltd.
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Jiang WU, Study Director, Beijing Center for Disease Control and Prevention
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.